MHRA's November specials site registers: a routine refresh with a compliance use

What happened

On 10 November 2026 the MHRA replaced the October 2026 versions of its manufacturer's specials (MS) and MANSA site registers with November 2026 editions. They sit on the regulator's page covering licensed manufacturing sites for human and veterinary medicines. The record describes this as a continuation of a roughly monthly update cycle.

The record does not say which sites were added, amended or removed, and it gives no reason for any change. Nobody can tell from the publication notice alone whether the November edition changes the status of a particular supplier. The only way to find out is to read the registers themselves.

Why a routine update still matters

Manufacturer's specials licences are the UK mechanism under which unlicensed medicines are made to meet individual patient needs. Many pharmacies, hospitals and wholesalers rely on suppliers that hold them. For those buyers, a site register is a working reference, not background reading. It is a quick public check that a supplier holds the authorisation it claims.

The monthly rhythm means a register is a snapshot that goes stale. A supplier qualification file that cites the October version, or an undated screenshot, is out of step with what the regulator now publishes. This is a documentation point rather than a regulatory change, but it is the kind of gap auditors and inspectors tend to notice.

Regulatory context: manufacturing credentials are a recurring theme

The other regulatory records from 10 November are mostly about products. They show how often a manufacturing-side question can sit behind a regulatory timeline.

Cingulate's CEO said in a media interview that resubmission of CTx-1301 for ADHD awaits completion of outstanding CMC work after an FDA rejection. The company plans to resubmit as promptly as practicable but gave no assurance on timing or approval. The record does not detail the CMC issues, so no wider conclusion should be drawn about them.

The FDA also set a 22 November PDUFA date for Capricor's Duchenne cell therapy deramiocel after classing August's two-year HOPE-3 data and a narrower upper-limb indication as a major amendment. A major amendment extends the review clock, which is a reminder that late data and scope changes move dates. Atara's resubmitted tab-cel BLA now has a 31 March 2027 action date. On the approval side, the FDA granted accelerated approval to Inovio's VOCERYQ, used with the CELLECTRA 5PSP device, and Opus Genetics won approval for RYZUMVI in presbyopia.

These items concern US product decisions, not UK site licensing, and the records do not link them to the MHRA update. Together they show the range of regulatory work in a single day: product-level decisions with fixed dates, and infrastructure-level publications that keep supply chains verifiable.

Who is affected

The most direct audience is quality and supply-chain teams that buy from, or audit, UK specials manufacturers. They include procurement functions at pharmacies and hospital trusts, wholesalers, and contract partners who list MS-licensed sites in their approved supplier lists. Regulatory affairs staff supporting UK distribution should also confirm that any site named in their own documentation matches the current register.

Sponsors and manufacturers outside the UK are less exposed. Even so, anyone running a global supplier database that includes UK sites inherits the same refresh obligation.

On the wider regulatory picture, Infarmed said it held four bilateral meetings and discussed AI, new approach methodologies and patient involvement at the ICMRA summit and plenary on 3–6 November, and confirmed its role in the ICMRA reliance working group. The record does not say what the working group has decided or planned. It is a reminder that regulators are discussing how to rely on one another's work, but nothing in these records changes how UK site registers should be used today. AEMPS, for its part, gave favourable opinions to a batch of new generics at its November meeting, with the next meeting set for 1 December 2026.

What to watch

The first thing to watch is the next edition. If the cycle holds, a December version should follow, though the record gives no date. Teams that build a recurring check into their calendar will not need to track announcements.

The second is whether the registers show changes that touch your own suppliers. Because the record does not say what changed, a direct comparison with the October version is the only reliable method.

Beyond the registers, the ICMRA reliance discussions are worth following at a high level. The records do not indicate any near-term effect on UK specials or site registers, so any link should be treated as unconfirmed.